Skye Bioscience @skyebioscience

Our team has resolved a temporary website issue as we work through updates to the Spotlight section, which will be launching soon. Stay tuned for more details. $SKYE

Effectively treating a multifaceted disease like obesity requires different approaches and mechanisms for #weightloss. Skye COO Tu Diep shares some of the feedback we've been receiving from #obesity specialists, along with how nimacimab's distinct mechanism of action fits into…

Today's presentation at the European Association for the Study of Diabetes Annual Meeting shared results from our Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease. Demonstrating that nimacimab was safe, well-tolerated, and exhibited…

A recent major study in the journal PNAS compared daily calorie burn for people in 34 different countries and cultures around the world, finding total calorie burn per day similar across populations. These findings have led scholars to conclude that the strong evidence indicates…

The Obesity Science & Innovation Summit was an excellent opportunity to explore the future of obesity treatment and weight loss, with Skye CEO Punit Dhillon joining a group of industry leaders for the keynote panel. Highlighting the market opportunity and differentiation of…

What drives you? Skye COO Tu Deep, MSc, is driven by good science designed to help people live healthier lives. We recently spoke to Tu about his inspiration and journey in science and discovery. View the full version of the video here: youtube.com/watch?v=wezYib… #obesity $SKYE

Why is nimacimab different? Here’s a look at what differentiates our CB1 receptor inhibitor, with potential to avoid the baggage of past drugs and deliver weight loss without psychiatric side effects. With Phase 2a data expected in Q3/Q4 of this year, learn more about Skye and…

The full recording of our virtual KOL event is now available, providing perspectives and insights on our upcoming Phase 2a CBeyond™ study and CB1 inhibition as a mechanism for weight loss. View the full video here: youtube.com/watch?v=uC6I8n… $SKYE #obesity

Today, we reported results from two new preclinical DIO studies evaluating nimacimab. From blunting post-treatment “rebound” effects to additive weight loss benefits, new studies comparing nimacimab to monlunabant and comparing/adding it to tirzepatide show positive outcomes…

An Associate Professor of Medicine and Director of Systemic Metabolism Research at @nyulangone, Dr Marcus Goncalves, MD, PhD, holds a wealth of expertise in the systemic pathways that regulate body weight, muscle mass, and metabolism. Our final panelist during next week’s…

Today, we’ve announced that the final patient has completed 26 weeks of treatment in our Phase2a CBeyond™ clinical trial evaluating nimacimab for the treatment of #obesity and overweight, with topline data expected in late Q3/early Q4 2025. Alongside this news, we also shared…

Dr Sean Wharton, MD, FRCPC, PharmD, will join us during next week’s virtual KOL event, providing his perspectives on the obesity therapeutics landscape. As the Director of the Wharton Medical Clinic, Assistant Professor at The University of Toronto, and Adjunct Professor at both…

Join @skyebioscience for a virtual KOL event on Sep. 4 at 8am ET to discuss expectations and details of upcoming topline results from the Phase 2a CBeyond™ trial of nimacimab. The event will feature three distinguished obesity KOLs. Register: lifescievents.com/event/gw04qhka…

Meet Dr. Kevin Cannon, MD–a board-certified internist and featured KOL speaker for next week’s event. Practicing as a hospitalist for over 25 years and being actively engaged in clinical research for 18 years, he’s served as a primary investigator in more than 50 metabolic…

Skye will host a virtual KOL event on Thursday, September 4th at 8 AM ET, titled “Expert Panel on Peripheral CB1 Inhibition as a Mechanism for Weight Loss.” Discussing expectations and details of upcoming topline results from the Phase 2a CBeyond™ trial of nimacimab, join us to…

Skye’s differentiated peripherally-restricted CB1 inhibitor, nimacimab, has the potential to address the challenges of current #obesity treatments, reducing side effects, improving response rates, and providing longer-term weight loss. Explore our work and the current treatment…

Today we announced five upcoming investment and medical conferences the Skye team will participate in, from fireside chats and keynote panels to oral presentations. For the full list of details and access to the webcasts, please see today’s release: ir.skyebioscience.com/news-releases/……

We’re committed to applying the best practices from drug design through manufacturing, with an ambitious goal of advancing new drug candidates to help with important unmet needs. Learn more about our pipeline here: skyebioscience.com/#pipeline #obesity $SKYE

We’re committed to developing next-generation anti-obesity therapeutics to meet this unprecedented unmet need. Learn more about the current #obesity treatment landscape here: skyebioscience.com/obesity/ $SKYE

The potential to address unmet needs in #obesity has never been higher. By targeting well-proven biological pathways, we’re continuing our work at $SKYE to meet these needs. Explore our pipeline and current Phase 2a trials with nimacimab here: skyebioscience.com/#pipeline